PurposeThis study aims to create predictive models of medication non-adherence by using digital markers that identify high risk environmental triggers and behavioral patterns. |
MethodSubjects take Abilify MyCite, an FDA approved ingestible sensor system to monitor medication adherence and use the Beiwe app to measure their sociability and mobility. |
CollectionParticipants take the digital Abilify MyCite tablets for three months while social, behavioral, and cognitive markers using smartphone-based digital phenotyping are simultaneously tracked.
|
InterpretationOur team analyzes the data collected from the Abilify MyCite digital tablet system and identifies features of passively (and actively) collected data that are associated with non-adherence and adherence.
|
ImplementationOur findings will inform the effectiveness and feasibility of a digital tablet as well as future use cases in predicting medication adherence and identifying digital signatures of symptom changes in mental illnesses.
|
Interested in participating?
|
Eligibility criteria:
Study Details: This study involves 6 visits to the Massachusetts Mental Health Center (75 Fenwood Road, Boston) over 5 months. Participants can receive up to $425 for completion of the study. |
|
Relevant Reading
- Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factorsfor medication nonadherence in patients with schizophrenia: a comprehensivereview of recent literature. The Journal of clinical psychiatry. 2002 Oct.
- Gibson S, Brand SL, Burt S, Boden ZV, Benson O. Understanding treatment non-adherencein schizophrenia and bipolar disorder: a survey of what service users do and why. BMC psychiatry. 2013 Dec;13(1):153.
- Higashi K, Medic G, Littlewood KJ, Diez T, Granstrom O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of non adherence, a systematic literature review. Therapeutic advances in psychopharmacology. 2013 Aug;3(4):200-18.
- Bain EE, Shafner L, Walling DP, Othman AA, Chuang-Stein C, Hinkle J, Hanina A. Useof a novel artificial intelligence platform on mobile devices to assess dosing compliance in a phase 2 clinical trial in subjects with schizophrenia. JMIRmHealth and uHealth. 2017 Feb;5(2).
- BarnettI, Torous J, Staples P, Sandoval L, Keshavan M, Onnela JP. Relapse prediction in schizophrenia through digital phenotyping: a pilot study.Neuropsychopharmacology. 2018 Feb 22:1.
